Editors: "Thomas C. Chen(Thomas C. )", "Marc Chamberlain(Marc )"

Avastin and Malignant Gliomas

Volume 1

eBook: US $79 Special Offer (PDF + Printed Copy): US $158
Printed Copy: US $119
Library License: US $316
ISSN: 2210-5565
ISBN: 978-1-60805-519-7
eISBN: 978-1-60805-132-8 (Online)
DOI: 10.2174/97816080513281100101
(0 Comment) | Rate This Book

Introduction

Neuro-oncology is an embryonic field of cancer research with a number of clinical trials in progress. However, the prognosis on neuro-oncologic patients has remained poor. Moreover, several small scale phase I/II trials performed have proved to be inconclusive because of the limited number of patients involved. As a result, many controversies exist in neuro-oncology drug development for which a forum does not exist. This ebook presents a detailed account on the use of avastin in treating cancer patients. A discussion on clinical experiences and the controversial debate among researchers of avastin's role in restricting malignant gliomas is also included giving readers a diverse perspective on the rationale of treating CNS tumors.

Foreword

- Pp. i
Victor A. Levin
Download Free

Preface

- Pp. ii-iiii (2)
Thomas Chen
Download Free

Contributors

- Pp. iv-vii (4)
Thomas C. Chen and Marc Chamberlain
Download Free

The Basic Science of Avastin (Bevacizumab) Therapy

- Pp. 1-6 (6)
Florence M. Hofman and Thomas C. Chen

PDF Price: $30

View Abstract Purchase Chapter

Avastin for Recurrent Malignant Gliomas

- Pp. 7-11 (5)
Annick Desjardins and James J. Vredenburgh

PDF Price: $30

View Abstract Purchase Chapter

Avastin and Malignant Gliomas: Is there a Role?

- Pp. 12-18 (7)
Teri N. Kreisl

PDF Price: $30

View Abstract Purchase Chapter

Bevacizumab with Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas

- Pp. 19-23 (5)
Fabio M. Iwamoto and Philip H. Gutin

PDF Price: $30

View Abstract Purchase Chapter

Bevacizumab Failure in Patients with Recurrent Malignant Glioma

- Pp. 24-27 (4)
Andrew D. Norden

PDF Price: $30

View Abstract Purchase Chapter

An Update on the Role of Anti-Angiogenic Therapy for Newly Diagnosed Glioblastoma

- Pp. 28-32 (5)
David A. Reardon, Sith Sathornsumetee and James V. Vredenburgh

PDF Price: $30

View Abstract Purchase Chapter

Bevacizumab Plus Radiotherapy in Malignant Gliomas: Is there a Role?

- Pp. 33-39 (7)
Minesh Mehta, Disha Patel and Arnab Chakravarti

PDF Price: $30

View Abstract Purchase Chapter

Bevacizumab and Malignant Glioma: Is there a Role for Upfront Therapy?

- Pp. 40-45 (6)
Jing Wu and Mark R. Gilbert

PDF Price: $30

View Abstract Purchase Chapter

Bevacizumab Toxicity in Glioblastoma

- Pp. 46-50 (5)
Dawit Aregawi and David Schiff

PDF Price: $30

View Abstract Purchase Chapter

Is Bevacizumab Administration Safe When Combined with Therapeutic Anticoagulation in Patients with High-grade Glioma?

- Pp. 51-53 (3)
Lisa R. Rogers

PDF Price: $30

View Abstract Purchase Chapter

Bevacizumab in the Treatment of Glioblastoma: Is there an Optimal Dose or Schedule?

- Pp. 54-58 (5)
L. Kamsheh, P. Kumthekar and J. J. Raizer

PDF Price: $30

View Abstract Purchase Chapter

Assessing Radiographic Response in Glioblastoma Following Avastin Treatment

- Pp. 59-73 (15)
Whitney B. Pope

PDF Price: $30

View Abstract Purchase Chapter

The Radiographic Interpretation of Response to Avastin in Glioblastoma Multiforme

- Pp. 74-80 (7)
Nicholas Butowski and Susan Chang

PDF Price: $30

View Abstract Purchase Chapter

Imaging Responses of Bevacizumab

- Pp. 81-93 (13)
R. Thind, Y. S. Mohan and T. Mikkelsen

PDF Price: $30

View Abstract Purchase Chapter

Assessing Radiographic Response to Bevacizumab in Patients with GBM

- Pp. 94-99 (6)
John W. Henson and Bart Keogh

PDF Price: $30

View Abstract Purchase Chapter

Neurosurgical Implications of Bevacizumab Therapy of Malignant Gliomas

- Pp. 100-106 (7)
Manish K. Aghi and Mitchel S. Berger

PDF Price: $30

View Abstract Purchase Chapter

Neurosurgical Implications of Avastin

- Pp. 107-110 (4)
Gazanfar Rahmathulla and Michael A. Vogelbaum

PDF Price: $30

View Abstract Purchase Chapter

Novel Applications for Bevacizumab and other Angiogenic Inhibitors

- Pp. 111-116 (6)
Marc C. Chamberlain

PDF Price: $30

View Abstract Purchase Chapter

Role of Avastin for Treatment of Central Nervous System Radiation Necrosis

- Pp. 117-126 (10)
Jing Wu and Victor A. Levin

PDF Price: $30

View Abstract Purchase Chapter

Salvage Chemotherapy with Bevacizumab for Recurrent Anaplastic Glioma

- Pp. 127-132 (6)
Marc C. Chamberlain

PDF Price: $30

View Abstract Purchase Chapter

Bevacizumab for Recurrent Glioma - A Personal View

- Pp. 133-139 (7)
Roger Stupp

PDF Price: $30

View Abstract Purchase Chapter

Inhibitors of VEGF Signaling Pathways in Glioblastoma: Is the Evidence Sufficient for Widespread Use? A European Perspective

- Pp. 140-143 (4)
M. J. van den Bent

PDF Price: $30

View Abstract Purchase Chapter

Bevacizumab (AvastinĀ®) and Malignant Glioma: Is there a Role? A European Perspective

- Pp. 144-146 (3)
Michael Weller

PDF Price: $30

View Abstract Purchase Chapter

The European Perspective Regarding Avastin and Malignant Gliomas

- Pp. 147-151 (5)
Wolfgang Wick, Michael Platten and Antje Wick

PDF Price: $30

View Abstract Purchase Chapter

Sunitinib for the Treatment of Central Nervous System Glioma

- Pp. 152-157 (6)
Neyns Bart

PDF Price: $30

View Abstract Purchase Chapter

Cilengitide: A Novel Integrin Antagonist, in Malignant Glioma

- Pp. 158-161 (4)
L. Burt Nabors

PDF Price: $30

View Abstract Purchase Chapter

Development of Sorafenib in Malignant Gliomas: Rationale and Early Clinical Experience

- Pp. 162-170 (9)
Rachel Grossman and Jaishri Blakeley

PDF Price: $30

View Abstract Purchase Chapter

Aflibercept (VEGF-Trap) in High-Grade Gliomas

- Pp. 171-175 (5)
Jan Drappatz, Andrew D. Norden and Patrick Y. Wen

PDF Price: $30

View Abstract Purchase Chapter

Cediranib in Glioblastoma

- Pp. 176-183 (8)
Elizabeth R. Gerstner, Jorg H. Dietrich, Daphne Wang and Tracy T. Batchelor

PDF Price: $30

View Abstract Purchase Chapter

Bevacizumab for Malignant Gliomas: Comparative Study with Other Malignancies

- Pp. 184-189 (6)
Helen Gu and Thomas C. Chen

PDF Price: $30

View Abstract Purchase Chapter

Author Index

- Pp. 190-191 (2)
Thomas C. Chen and Marc Chamberlain
Download Free

Index

- Pp. 192-195 (4)
Bentham Science Publishers
Download Free

RELATED BOOKS

.Cutting Edge Therapies for Cancer in the 21 Century.
.Cancer Immunotherapy: Mechanisms of Cancer Immunity, Engineering Immune-Based Therapies and Developing Clinical Trials.
.Systems Biology in Cancer Immunotherapy.